for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SEIKAGAKU CORPORATION

4548.T

Latest Trade

1,254.00JPY

Change

6.00(+0.48%)

Volume

41,000

Today's Range

1,241.00

 - 

1,265.00

52 Week Range

1,073.00

 - 

1,594.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1,248.00
Open
1,241.00
Volume
41,000
3M AVG Volume
1.45
Today's High
1,265.00
Today's Low
1,241.00
52 Week High
1,594.00
52 Week Low
1,073.00
Shares Out (MIL)
56.40
Market Cap (MIL)
70,506.29
Forward P/E
31.82
Dividend (Yield %)
2.10

Next Event

Q3 2020 Seikagaku Corp Earnings Release

Latest Developments

More

Seikagaku says clinical trial for SI-449

Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SEIKAGAKU CORPORATION

SEIKAGAKU CORPORATION is principally engaged in the research, development, purchase, manufacture and sale of pharmaceutical products and limulus amebocyte lysate (LAL). The Company operates in two business segments. The Pharmaceutical business segment provides hyaluronan-based medicines for joint function improvement, ophthalmic operation boosters and submucosal injection materials for endoscopes, as well as drug substances for various pharmaceuticals. The LAL business segment provides reagents for measuring endotoxin.

Industry

Biotechnology & Drugs

Contact Info

10F, Marunouchi Center Bldg

1-6-1, Marunouchi

+81.3.52208950

http://www.seikagaku.co.jp

Executive Leadership

Ken Mizutani

President, Chief Director of Production, Representative Director

Toshiyuki Okada

Managing Executive Officer, Chief Director of Business Promotion, Director

Yoshiyuki Sakura

Managing Executive Officer, Director of Production Technology in Main Production Unit, Director of General Affairs

Takayuki Akita

Senior Executive Officer, Director of Business Planning, Director

Yosuke Funakoshi

Senior Executive Officer, Chief Director of Research & Development, Director of Clinical Development, Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

31.550

2018

69.300

2019

39.760

2020(E)

39.000
Price To Earnings (TTM)
34.65
Price To Sales (TTM)
2.45
Price To Book (MRQ)
0.96
Price To Cash Flow (TTM)
14.32
Total Debt To Equity (MRQ)
0.51
LT Debt To Equity (MRQ)
0.06
Return on Investment (TTM)
2.68
Return on Equity (TTM)
2.51

Latest News

Latest News

BRIEF-Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan

* Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation

BRIEF-Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603

* Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation.

BRIEF-Ribomic signs collaborative research contract with SEIKAGAKU

* Says it signed collaborative research contract with SEIKAGAKU CORPORATION

BRIEF- Seikagaku initiates phase II study of SI-613 for treatment of knee osteoarthritis in U.S.

* Says it announces the start of phase II study of SI-613 in patients with osteoarthritis of the knee, in the U.S.

BRIEF- Ono Pharmaceutical signs co-development and marketing collaboration agreement with Seikagaku

* Says Seikagaku Corp and Ono Pharmaceutical Co., Ltd. have reached a basic agreement related toco-development and marketing collaboration on SI-613 under development by Seikagaku for the treatment of osteoarthritis in Japan

BRIEF-Seikagaku signs exclusive distribution agreement with Zimmer Biomet Holdings, Inc.

* Say it signed an agreement with Zimmer Biomet Holdings, Inc. to grant Zimmer Biomet Holdings, Inc. the exclusive distribution rights in the U.S. on the joint function improver "VISCO-3TM"

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up